Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$4.33
$4.39
50-Day Range
$4.30
$4.41
52-Week Range
$1.37
$4.58
Volume
481,600 shs
Average Volume
69,080 shs
Market Capitalization
$37.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.63
Consensus Rating
Buy

Company Overview

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Remove Ads
Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

Lumos Pharma Completes Merger and Delisting Process
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Lumos Pharma reports sustained growth in PGHD trials
See More Headlines

LUMO Stock Analysis - Frequently Asked Questions

Lumos Pharma, Inc. (NASDAQ:LUMO) announced its earnings results on Thursday, November, 7th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.34. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%.

Top institutional investors of Lumos Pharma include Concourse Financial Group Securities Inc.. Insiders that own company stock include John C Mckew, Thomas A Raffin and Richard J Hawkins.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

Last Earnings
11/07/2024
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LUMO
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.63
High Stock Price Target
$13.00
Low Stock Price Target
$4.25
Potential Upside/Downside
+98.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-34,030,000.00
Net Margins
-1,583.49%
Pretax Margin
-1,583.49%

Debt

Sales & Book Value

Annual Sales
$2.21 million
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
1.26

Miscellaneous

Free Float
6,452,000
Market Cap
$37.54 million
Optionable
Not Optionable
Beta
0.74
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LUMO) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners